Evidence map›Paper›PMID 38245513›Full record

Trial reportNature communications2024

Engineering tumor-colonizing E. coli Nissle 1917 for detection and treatment of colorectal neoplasia.

Candice R Gurbatri, Georgette A Radford, Laura Vrbanac, Jongwon Im, Elaine M Thomas, Courtney Coker, Samuel R Taylor, YoungUk Jang, Ayelet Sivan, Kyu Rhee and 27 more

Open access · goldAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers.

0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed
54.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

103 citing papers in PubMed, 141 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. BiohybridMaterials today. Bio · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Therapeutic bacteria-trained NK cells confer long-term protection against cancer metastasis.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  13. Living Microbial Drugs.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. The Role of Selected Bacteria in Breast Cancer Initiation and Development.International journal of molecular sciences · 2026
    Review

43 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors at 9 institutions in 2 countries.

Candice R Gurbatri *Department of Biomedical Engineering, Columbia University, New York, NY, 10027, USA.
Georgette A Radford *Adelaide Medical School, University of Adelaide, Adelaide, SA, 5000, Australia.
Laura VrbanacAdelaide Medical School, University of Adelaide, Adelaide, SA, 5000, Australia.
Jongwon ImDepartment of Biomedical Engineering, Columbia University, New York, NY, 10027, USA.ORCID 0000-0002-3660-2770
Elaine M ThomasAdelaide Medical School, University of Adelaide, Adelaide, SA, 5000, Australia.
Courtney CokerDepartment of Biomedical Engineering, Columbia University, New York, NY, 10027, USA.ORCID 0000-0002-8779-133X
Samuel R TaylorWeill Cornell-Rockefeller-Sloan Kettering Tri-Institutional MD-PhD program, New York, NY, USA.ORCID 0000-0002-0926-9394
YoungUk JangDepartment of Biomedical Engineering, Columbia University, New York, NY, 10027, USA.
Ayelet SivanDepartment of Biomedical Engineering, Columbia University, New York, NY, 10027, USA.
Kyu RheeDivision of Infectious Diseases, Weill Department of Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0003-4582-2895
Anas A SalehDivision of Infectious Diseases, Weill Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Tiffany ChienDepartment of Biomedical Engineering, Columbia University, New York, NY, 10027, USA.
Fereshteh ZandkarimiDepartment of Chemistry, Columbia University, New York, NY, USA.ORCID 0000-0001-8618-3669
Ioana LiaDepartment of Biomedical Engineering, Columbia University, New York, NY, 10027, USA.
Tamsin R M LannaganAdelaide Medical School, University of Adelaide, Adelaide, SA, 5000, Australia.
Tongtong WangAdelaide Medical School, University of Adelaide, Adelaide, SA, 5000, Australia.ORCID 0000-0002-8807-2441
Josephine A WrightSouth Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, 5000, Australia.
Hiroki KobayashiAdelaide Medical School, University of Adelaide, Adelaide, SA, 5000, Australia.ORCID 0000-0002-1717-4870
Jia Q NgAdelaide Medical School, University of Adelaide, Adelaide, SA, 5000, Australia.
Matt LawrenceColorectal Unit, Department of Surgery, Royal Adelaide Hospital, Adelaide, SA, 5000, Australia.
Tarik SammourAdelaide Medical School, University of Adelaide, Adelaide, SA, 5000, Australia.
Michelle ThomasColorectal Unit, Department of Surgery, Royal Adelaide Hospital, Adelaide, SA, 5000, Australia.
Mark LewisColorectal Unit, Department of Surgery, Royal Adelaide Hospital, Adelaide, SA, 5000, Australia.
Lito PapanicolasSouth Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, 5000, Australia.
Joanne PerryColorectal Unit, Department of Surgery, Royal Adelaide Hospital, Adelaide, SA, 5000, Australia.
Tracy FitzsimmonsColorectal Unit, Department of Surgery, Royal Adelaide Hospital, Adelaide, SA, 5000, Australia.
Patricia KaazanAdelaide Medical School, University of Adelaide, Adelaide, SA, 5000, Australia.
Amanda LimAdelaide Medical School, University of Adelaide, Adelaide, SA, 5000, Australia.ORCID 0000-0001-8172-9140
Alexandra M StavropoulosAdelaide Medical School, University of Adelaide, Adelaide, SA, 5000, Australia.
Dion A GouskosAdelaide Medical School, University of Adelaide, Adelaide, SA, 5000, Australia.
Julie MarkerCancer Voices SA, Adelaide, South Australia, Australia.
Cheri OstroffUniversity of South Australia, Adelaide, South Australia, 5000, Australia.ORCID 0000-0003-1067-6226
Geraint RogersSouth Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, 5000, Australia.
Nicholas ArpaiaDepartment of Microbiology & Immunology, Vagelos College of Physicians and Surgeons of Columbia University, New York, NY, 10032, USA.ORCID 0000-0002-0657-0528
Daniel L WorthleySouth Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, 5000, Australia.ORCID 0000-0003-0374-9124
Susan L WoodsAdelaide Medical School, University of Adelaide, Adelaide, SA, 5000, Australia. susan.woods@adelaide.edu.au.ORCID 0000-0002-8955-2017
Tal DaninoDepartment of Biomedical Engineering, Columbia University, New York, NY, 10027, USA. td2506@columbia.edu.ORCID 0000-0003-2713-7659
The University of Adelaide · AUColumbia University · USRoyal Adelaide Hospital · AUSouth Australian Health and Medical Research Institute · AUCornell University · USColumbia University Irving Medical Center · USFlinders University · AUBrisbane Hand & Upper Limb Research Institute · AUUniversity of South Australia · AU

Funding

Modulation of the tumor microenvironment with probiotic therapiesR01CA249160 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI ARPAIA, NICHOLAS, DANINO, TAL · 2020 to 2024
$3.0M
Engineering immunotherapeutic probiotics to mitigate irAEU01CA247573 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI ARPAIA, NICHOLAS, DANINO, TAL · 2020 to 2024
$2.9M
NCI NIH HHS R01 CA249160NCI NIH HHS U01 CA247573
6 · The paper itself

Abstract

Bioengineered probiotics enable new opportunities to improve colorectal cancer (CRC) screening, prevention and treatment. Here, first, we demonstrate selective colonization of colorectal adenomas after oral delivery of probiotic E. coli Nissle 1917 (EcN) to a genetically-engineered murine model of CRC predisposition and orthotopic models of CRC. We next undertake an interventional, double-blind, dual-centre, prospective clinical trial, in which CRC patients take either placebo or EcN for two weeks prior to resection of neoplastic and adjacent normal colorectal tissue (ACTRN12619000210178). We detect enrichment of EcN in tumor samples over normal tissue from probiotic-treated patients (primary outcome of the trial). Next, we develop early CRC intervention strategies. To detect lesions, we engineer EcN to produce a small molecule, salicylate. Oral delivery of this strain results in increased levels of salicylate in the urine of adenoma-bearing mice, in comparison to healthy controls. To assess therapeutic potential, we engineer EcN to locally release a cytokine, GM-CSF, and blocking nanobodies against PD-L1 and CTLA-4 at the neoplastic site, and demonstrate that oral delivery of this strain reduces adenoma burden by ~50%. Together, these results support the use of EcN as an orally-deliverable platform to detect disease and treat CRC through the production of screening and therapeutic molecules.

Indexed as

AdenomaColorectal NeoplasmsAnimalsDouble-Blind MethodEscherichia coliHumansMiceProspective StudiesSalicylatesSalicylates

Identifiers

PMID38245513
PMCPMC10799955
OpenAlexW4391044494

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.